NCT02346721View on ClinicalTrials.gov

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

February 23, 2015

Primary Completion Date

March 23, 2016

Study Completion Date

June 15, 2016

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

SOF/VEL

400/100 mg tablet administered orally once daily

Trial Locations (61)

1070

Brussels

2060

Antwerp

13008

Marseille

15213

Pittsburgh

15240

Pittsburgh

19104

Philadelphia

20099

Hamburg

21202

Baltimore

23226

Richmond

30066

Marietta

30308

Atlanta

30625

Hanover

31059

Toulouse

32256

Jacksonville

33136

Miami

33414

Wellington

33604

Pessac

37211

Nashville

38138

Germantown

40237

Düsseldorf

46237

Indianapolis

50012

Florence

50932

Cologne

59037

Lille

63000

Clermont-Ferrand

69004

Lyon

71013

San Giovanni Rotondo

75014

Paris

80045

Aurora

81377

München

87042

Limoges

90027

Los Angeles

90036

Los Angeles

90048

Los Angeles

90822

Long Beach

92110

Clichy

92123

San Diego

92154

San Diego

94000

Créteil

94304

Palo Alto

94804

Villejuif

95817

Sacramento

32610-0272

Gainesville

02129

Boston

02905

Providence

T6G 2B7

Edmonton

V5Z 1M9

Vancouver

V6Z2C7

Vancouver

H2X 0A9

Montreal

M5T 2S8

Toronto

D-10969

Berlin

Unknown

Hong Kong

09027

San Juan

PL6 8DH

Plymouth

PO6 3LY

Portsmouth

G12 0YN

Glasgow

E1 4AT

London

NW3 2PF

London

W2 1NY

London

M8 5RB

Manchester

OX3 9DU

Oxford

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY